Pfizer share news, announcements and annual reports
NSE: PFIZERBSE: 500680Pharmaceuticals & BiotechnologySmall Cap
Pfizer Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 1966 on BSE, Apr 1999 on NSE
Last close ₹3,638.70down ₹49.10 (1.33%)BSE ₹3,637.90
Share price at the NSE close on 2 Nov 2026. Previous close ₹3,687.80.
2 Nov: open ₹3,687.80, high ₹3,718.20, low ₹3,613.60
52-week range of traded prices to 2 Nov 2026
₹3,589.00Low, 23 Oct 2026₹5,339.00High, 13 Nov 2025
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹16,646 Cr327th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 22.64
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.96
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.06%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 55,74259.3% delivered
Pfizer share news and announcements
659 announcements, routine notices left out, newest first. Page 12 of 14.
Aug 2012
1 Aug · Board meeting
Inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2012.
Jul 2012
10 Jul · Meeting
Register of Members and the Share Transfer Books of the Company will remain closed from July 26, 2012 to August 02, 2012 (both days inclusive) for the purpose of determining the eligibility of payment of dividend. The said dividend, if declared at the Annual General Meeting, will be paid on August 16, 2012. Further, the Annual General Meeting of the Company is scheduled to be held on August 02, 2012.
Jun 2012
28 Jun · Board meeting
Board of Directors of the Company at their Meeting held on June 28, 2012 accepted the resignation of Mr. Kewal Handa as the Director and Managing Director of the Company with effect from the end of day on August 15, 2012. Mr. Kewal Handa would continue as an employee of the Company until his retirement from the Company i.e. August 31, 2012. Further, the Board of Directors of the Company at their Meeting held on June 28, 2012 appointed Mr. Aijaz Tobaccowalla as an Additional Director of the Company with immediate effect. Further, the Board of Directors of the Company at their Meeting held on June 28, 2012 also appointed Mr. Aijaz Tobaccowalla as the Managing Director of the Company with effect from August 16, 2012 subject to approval of shareholders and Central Government.
May 2012
21 May · Management
Dr. Bomi M. Gagrat, Non-Executive Director has resigned from the Board of Directors of the Company with effect from the close of business hours on May 21, 2012.21 May · Management
Board of Directors of the Company at their meeting held on May 21, 2012 appointed the following Additional Directors on the Board of the Company with effect from May 21, 2012: (1) Mr. Uday Khanna; (2) Mr. Sunil Madhok, designated as Executive Director, Business Operations; (3) Mr. Vivek Dhariwal, designated as Executive Director, Technical Operations. The appointment and remuneration of Mr. Madhok and Mr. Dhariwal, Whole-time Directors will be subject to the approval of the shareholders in the ensuing Annual General Meeting of the Company.21 May · Dividend
Board of Directors at its meeting held on May 21, 2012 has recommended a dividend of Rs.12.50/- per Equity share of Rs.10 each (125%) for the year ended March 31, 2012. The Said dividend, if declared at the ensuing Annual General Meeting of the Company, shall be paid on August 16, 2012.21 May · Results
10 May · Board meeting
Inter alia to consider and approve the Audited Financial Results of the Company for the year ended March 31, 2012 and to recommend dividend thereon.
Apr 2012
25 Apr · Results
Company proposes to announce the audited results for the financial year ended March 31, 2012 within the 60 days period as stipulated in clause 41 of the Listing Agreement. Hence, the Company will not be publishing the un-audited results for the last quarter ended March 31, 2012.
Mar 2012
Feb 2012
Jan 2012
19 Jan · Board meeting
Inter-alia to consider and approve the unaudited Financial Results of the Company for the 3rd quarter ended December 31, 2011.5 Jan · Updates
Board of Directors of the Company, at its meeting held on January 05, 2012, has approved the incorporation of a wholly owned subsidiary in the State of Maharashtra, with a view to spin off its animal health business to such entity as a pre-step to subsequent sale to a wholly owned subsidiary of Pfizer Inc., in India, subject to all approvals and permissions.
Oct 2011
11 Oct · Board meeting
Inter-alia to consider and approve the Unaudited Financial Results of the Company for the 2nd quarter ended September 30, 2011.
Aug 2011
1 Aug · Results
Standalone Results for the quarter ended on 30-JUN-2011 as follows: Net Sales of Rs. 24187 lacs for quarter ending on 30-JUN-2011. Net Profit / (Loss) of Rs. 4124 lacs for the quarter ending on 30-JUN-2011.
Jul 2011
22 Jul · Board meeting
Inter-alia to consider and approve the Unaudited Financial Results of the Company for the 1st quarter ended June 30, 2011.20 Jul · Meeting
Annual General Meeting (AGM) of the Company was held on July 19, 2011. All the items of business contained in the Notice of the Annual General Meeting of the Company were approved by the Members with requisite majority, namely, (1) Adoption of the Audited Balance Sheet as at March 31, 2011, Profit and Loss Accounts for the 16 months period December 01, 2009 to March 31, 2011 and the Reports of the Board of Directors and Auditors thereon; (2) Declaration of Final Dividend of Rs.4.00 per equity share of Rs.10/- each for the 16 months period ended March 31, 2011; (3) Re-appointment of Mr. R. A. Shah, as Director retiring by rotation; (4) Appointment of Auditors M/s. B S R & Co. until the conclusion of next AGM of the Company.1 Jul · Updates
Dr. Bomi M. Gagrat, Executive Director - Technical Operations has retired from the services of the Company from the close of business hours on June 30, 2011. Dr. Bomi M. Gagrat would continue as Non- Executive Director on the Board of the Company with effect from July 01, 2011.
Jun 2011
7 Jun · Meeting
Register of Members and the Share Transfer Books of the Company will remain closed from July 12, 2011 to July 19, 2011 (both days inclusive) for the purpose of payment of final dividend. The said dividend, if declared at the forthcoming Annual General Meeting, will be paid/ dispatched on August 2, 2011. The Annual General Meeting of the Company is scheduled to be held on July 19, 2011.
May 2011
3 May · Dividend
Board of Directors at its meeting held on May 03, 2011, has recommended a final dividend of Rs. 4.00 per Equity Share of Rs.10/- each (40%) for the 16 months period December 01, 2009 to March 31, 2011.The said final dividend shall be paid/dispatched on August 02, 2011.
Apr 2011
21 Apr · Board meeting
Inter-alia to consider and approve the Audited Financial Results of the Company for the 16 months period December 01, 2009 to March 31, 2011 and to recommend final dividend, thereon, if any.11 Apr · Results
Company propose to publish the Audited Financial Results for the 16 months period ended March 31, 2011 alongwith the Un-audited Financial Results for the 4 months period from December 01, 2010 to March 31, 2011 within a period of 60 days as stipulated in Clause 41 of the Listing agreement. Therefore, Company will not be separately publishing the Un-audited Financial Results for the 5th Quarter i.e. for the 4 months period December 01, 2010 to March 31, 2011.
Jan 2011
11 Jan · Corporate action
Board of Directors of the Company has fixed January 21, 2011 as the 'Record Date' for the purpose of payment of Interim Dividend.11 Jan · Management
Mr. Richard Gane has resigned as a Director of the Company with effect from close of business on January 11, 2011.11 Jan · Dividend
Board of Directors of the Company at its meeting held on January 11, 2011, declared an Interim Dividend of Rs. 12.50/- per Equity share of Rs. 10 each (125%) for the current financial year ending March 31, 2011 i.e. 16 months period commencing from December 01, 2009 to March 31, 2011. The said Interim Dividend shall be paid / dispatched on January 31, 2011.11 Jan · Results
Standalone Results for the period ended on 30-NOV-2010 as follows: Net Sales of Rs. 23584 lacs for period ending on 30-NOV-2010 against Rs. 19494 lacs for the period ending on 30-NOV-2009. Net Profit / (Loss) of Rs. 4358 lacs for the period ending on 30-NOV-2010 against Rs. 2573 lacs for the period ending on 30-NOV-2009.
Dec 2010
29 Dec · Board meeting
Inter-alia to consider and approve the Unaudited Financial Results for the 4th Quarter ended November 30, 2010.
Nov 2010
24 Nov · Change in Financial Year
Board of Directors of the Company has decided to change the Current Financial Year of the Company from December 01, 2009- November 30, 2010 to a 16 month period from December 01, 2009 to March 31, 2011, subject to the approval of the Registrar of Companies, Maharashtra, Mumbai under Section 210 (4). The Company has on November 23, 2010 made an application to the Registrar of Companies, Maharashtra, Mumbai, seeking approval for extension of the current Financial Year of the Company from December 01, 2009- November 30, 2010 to a 16 month period from December 01, 2009 to March 31, 2011.The subsequent Financial Years of the Company would be for the period April 01 to March 31. In view of the above, the Company will be publishing the quarterly Un-audited Financial Results for the quarters ended November 30, 2010 and February 28, 2011 within the required period in compliance with Listing Agreement. The Annual Financial Results of the Company will be prepared for a period of 16 months from December 01, 2009 to March 31, 2011.
Oct 2010
6 Oct · Results
Standalone Results for the quarter ended on 31-AUG-2010 as follows: Net Sales of Rs. 22561 lacs for quarter ending on 31-AUG-2010 against Rs. 20484 lacs for the quarter ending on 31-AUG-2009. Net Profit / (Loss) of Rs. 4248 lacs for the quarter ending on 31-AUG-2010 against Rs. 4115 lacs for the quarter ending on 31-AUG-2009.
Sep 2010
27 Sep · Board meeting
Inter-alia to consider and approve the Unaudited Financial Results for the 3rd quarter ended August 31, 2010.
Jul 2010
12 Jul · Results
Standalone Results for the quarter ended on 31-MAY-2010 as follows: Net Sales of Rs. 21233 lacs for quarter ending on 31-MAY-2010 against Rs. 18585 lacs for the quarter ending on 31-MAY-2009. Net Profit / (Loss) of Rs. 3469 lacs for the quarter ending on 31-MAY-2010 against Rs. 3129 lacs for the quarter ending on 31-MAY-2009.
Jun 2010
29 Jun · Board meeting
To consider and approve the Un-audited Financial Results for the Second quarter ended May 31, 2010.
May 2010
19 May · News Verification
News Verification : The media had reports that Pfizer Limited may buy a controlling stake in Piramal Healthcare Limited. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Pfizer Limited has vide its letter inter-alia stated," We wish to inform you that as a policy we do not comment on market rumours and speculations."
Mar 2010
30 Mar · Meeting
Pfizer Ltd. has informed the Exchange that the Register of Members and the Share Transfer Books of the Company will remain closed from April 17, 2010 to April 26, 2010 (both days inclusive) for the purpose of determining the eligibility of payment of Dividend. The dividend, if declared at the forthcoming Annual General Meeting, will be paid on May 12, 2010. The Annual General Meeting of the Company is scheduled to be held on April 26, 2010.26 Mar · Results
Pfizer Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 28-FEB-2010 as follows: Net Sales of Rs. 20261 lacs for quarter ending on 28-FEB-2010 against Rs. 18597 lacs for the quarter ending on 28-FEB-2009. Net Profit / (Loss) of Rs. 4245 lacs for the quarter ending on 28-FEB-2010 against Rs. 3901 lacs for the quarter ending on 28-FEB-2009.19 Mar · Board meeting
Pfizer Ltd. has informed the Exchange regarding the outcome of Board meeting held today for the reconsideration of financial results on account of Court Approval to the Scheme of Amalgamation between Duchem Laboratories Limited (the unlisted wholly-owned subsidiary) with Pfizer Limited. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Mar · Board meeting
Interalia to consider and approve the Unaudited Financial Results for the 1st Quarter ended February 28, 2010.18 Mar · Board meeting
Company proposes to reconsider the audited Financial Results of the merged entity i.e. Pfizer Ltd. and Duchem Laboratories Ltd. A meeting of the Board of Directors of Pfizer Ltd. would be held on March 19, 2010, to reconsider and approve the Annual Financial Results of the merged entity with a view to give effect to the Court order.15 Mar · Business
Pfizer Ltd. has informed the Exchange that the Bombay High Court vide its Order dated February 26, 2010, has sanctioned the Scheme of Amalgamation of Duchem Laboratories Ltd., the unlisted wholly-owned subsidiary with Pfizer Ltd. A copy of the said Order is being filed with Registrar of Companies, Maharashtra, Mumbai. Further the Company noted that, the appointed date of the said Scheme of Amalgamation is December 01, 2008.